PDB49 - Evaluation of the Cost Per Patient Achieving Composite and Single Treatment Targets with Once-Weekly Semaglutide and Exenatide ER in the United States
- Resource Type
- Abstract
- Source
- In
Value in Health May 2018 21 Supplement 1:S74-S75 - Subject
- Language
- ISSN
- 1098-3015